Sylvant
Sylvant ingredients
| Active ingredient | Strength |
|---|---|
| Siltuximab | 100 mg/1, 400 mg/1 |
What Sylvant is used for
The FDA lists the approved uses on the official label (below). In the EU, siltuximab is approved as Sylvant for:
Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Sylvant
- Generic name
- Siltuximab
- Made by
- Recordati Rare Diseases, Inc.
- Forms
- Injection, Powder, For Solution
- Given
- Intravenous
- Drug class
- Interleukin-6 Antagonist
- FDA approval
- Biologic licence (BLA) BLA125496
- On the US market since
- 2014
Official information
- Sylvant prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Siltuximab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Sylvant?
Sylvant (Siltuximab) is a specialist medicine made by Recordati Rare Diseases, Inc., approved by the US FDA.
What are the ingredients of Sylvant?
Sylvant contains Siltuximab (100 mg/1, 400 mg/1).
Is Sylvant approved in Europe?
The same active substance is approved in the EU as Sylvant.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA